Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 65%
filed 2026-06-03
Item 7.01
Cardiff Oncology disclosed Phase 2 CRDF-004 clinical trial data and registrational study plans for onvansertib via an investor presentation under Regulation FD. While this represents material clinical development information that would affect investor assessment of the company's pipeline and regulatory pathway, it does not fit neatly into the standard taxonomy categories (not an earnings release, M&A activity, executive change, or other specifically defined event). The disclosure is material because clinical trial results and regulatory strategy are central to a biotech company's valuation and investor decision-making.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
ATI Inc. announced its intention to conduct an underwritten public offering of seven-year senior notes. While this is a material financing event that would affect investor assessment of the company's capital structure and liquidity, it does not fit neatly into the more specific categories (dilutive_issuance applies to equity, not debt; ma_activity covers acquisitions/dispositions). The disclosure is material but represents a debt financing announcement rather than a discrete event type in the taxonomy.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
CECONY entered into an underwriting agreement on June 1, 2026 to issue $1.3 billion in aggregate principal amount of debentures ($450 million 5.15% due 2036 and $850 million 5.875% due 2056). While this is a material debt issuance affecting the registrant's capital structure and financial position, it does not fit the specific taxonomy categories: it is not a dilutive equity issuance (Item 3.02), not a material acquisition or disposition (Item 1.01/2.01), and not a restatement, auditor change, or other enumerated event. The disclosure is material to investors as it represents a significant financing activity, but the most appropriate classification is other_material given the absence of a dedicated debt issuance category.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-03
Item 5.03
FONAR amended and restated its Certificate of Incorporation effective at the Effective Time of the merger, and modified security holder rights in connection with the transaction.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
PG&E completed a $2.2 billion debt issuance of First Mortgage Bonds across three tranches (2031, 2036, and 2056 maturities) on June 3, 2026. While material financing activity, this does not fit the specific taxonomy categories: it is not M&A, not a dilutive equity issuance, and not a covenant breach or going-concern disclosure. The disclosure is material to investors as it reflects the company's capital structure and financing strategy, but the 8-K Item 8.01 treatment and the nature of the transaction (routine debt financing for a regulated utility) suggest classification as other_material rather than a more specific event type.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-03
Item 1.01
This disclosure describes entry into a dealer manager agreement for distribution of fund units and shares, with a servicing fee structure of up to 0.85% of NAV per annum. While Item 1.01 typically covers M&A activity, this agreement is a material definitive agreement governing the fund's distribution infrastructure and fee arrangements. The agreement is material to investors as it establishes the economic terms and distribution mechanism for the fund's securities, but does not fit cleanly into the M&A taxonomy (no acquisition, merger, or change of control is occurring).
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
Danaher completed a material private placement of CHF 2.26+ billion in senior unsecured notes across seven series with maturities from 2031 to 2056, with proceeds to be used for general corporate purposes including acquisitions and share repurchases.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
PSEG completed a $500 million public offering of senior notes due 2031 on June 3, 2026. While debt issuances are material financing events affecting the registrant's capital structure and financial position, this disclosure does not fit neatly into the more specific event categories (it is not M&A, a dilutive equity issuance, or a covenant breach). The filing is a routine debt offering disclosure under Item 8.01, making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-03
This 8-K discloses the issuance of $5 billion in debt securities ($2.5B 4.972% Fixed/Floating Rate Notes due 2032 and $2.5B 5.425% Fixed/Floating Rate Notes due 2037) by Goldman Sachs on June 3, 2026 pursuant to its shelf registration. While debt issuances are material financing events affecting the registrant's capital structure and liquidity, they do not fit neatly into the standard taxonomy categories (not M&A, not dilutive equity, not a restatement or going-concern issue). This is a material capital markets transaction disclosed via Item 9.01 (Exhibits).
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 8.01
Vroom disclosed amendments to two material warehouse credit facilities on May 29, 2026. Amendment No. 28 to Warehouse Credit Facility One extends the Commitment Termination Date by one month (June 2 to July 2, 2026), while Amendment No. 10 to Warehouse Credit Facility Two reduces advance rates, lowers the Minimum Tangible Net Worth covenant, and adjusts liquidity calculations. These amendments to material financing arrangements would affect a reasonable investor's assessment of the company's liquidity and financial flexibility, but the disclosures do not clearly indicate a covenant breach, going-concern issue, or other more specific event type—making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
ATI Inc. announced the pricing of an unsecured senior notes offering (5.875% due 2033) on June 3, 2026. This is a material debt issuance that would affect investor assessment of the company's capital structure and financial obligations, but it does not fit neatly into the more specific event categories (it is not a dilutive equity issuance, M&A activity, or a financial restatement). The disclosure is appropriately classified as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 55%
filed 2026-06-03
Item 7.01
The filing discloses an "operations and financial update" via press release filed with Canadian Securities Regulatory Authorities. While the Item 7.01 disclosure itself is vague and non-specific, the reference to a press release providing "operations and financial update" suggests material business information. Without access to the actual press release (Exhibit 99.1), the precise nature of the update cannot be determined—it could relate to earnings, material events, or other developments. Given the ambiguity and the Regulation FD safe-harbor language, this is classified as other_material rather than a more specific category.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-03
The filing discloses entry into Amendment No. 1 to an Intellectual Property License Agreement with BP United on June 1, 2026, which materially modifies the original IP Agreement dated May 12, 2026. The amendment restructures consideration (retaining $5M cash, issuing vesting shares), eliminates a planned Supply Agreement, and substitutes manufacturing and consulting services. While Item 1.01 is titled "Entry into a Material Definitive Agreement," the substance is an amendment that restructures an existing deal rather than a standalone M&A transaction, acquisition, or disposition. The materiality to investors is clear (cash retention, equity issuance, operational restructuring), but the event does not fit cleanly into the M&A taxonomy categories.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-03
The filing discloses two material debt events: (1) Amendment No. 1 extending the maturity of a $1.25M senior note from June 30, 2026 to November 15, 2026 and removing a prior event of default related to preferred share authorization; and (2) issuance of $312.5M in aggregate principal unsecured promissory notes due November 15, 2026 for $250K proceeds. While Item 1.01 (material definitive agreement) and Item 2.03 (direct financial obligation) are disclosed, the substance involves debt restructuring and new financing that does not cleanly fit the taxonomy categories—it is neither a covenant breach (no violation alleged), nor a going-concern disclosure, nor a dilutive issuance (debt, not equity). The extension of maturity and removal of a prior default event suggest financial stress, making this material to investors but best classified as other_material given the hybrid nature of debt amendment and new financing.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 1.01
The Company entered into a Software Development Agreement with Nexe Cloud Limited on May 28, 2026, to design and develop an enterprise business intelligence system spanning six major workstreams (architecture, infrastructure, data warehouse, integration, visualization, and analytics). While Item 1.01 typically covers M&A activity, this is a material service contract for enterprise software development with a first milestone payment of $300,000 and a one-year term. The scope and strategic importance (centralized intelligent ecosystem supporting enterprise-wide planning) suggest materiality, but the event does not fit the M&A taxonomy (no acquisition, merger, or change of control) and is best classified as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 7.01
The company disclosed on June 3, 2026 that it is "exploring strategic alternatives," which signals potential material corporate action such as a sale, merger, restructuring, or other significant strategic change. While the specific nature of the alternatives is not detailed in this Item 7.01 disclosure, the announcement itself is material to investors as it indicates the company is considering fundamental changes to its business or structure. This does not fit neatly into the M&A taxonomy categories (which typically require entry into, completion, or termination of a transaction) but represents a material event that would affect investor assessment of the registrant's future direction.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-03
The filing discloses the Company's intention to pursue a Commissioner's National Priority Review Voucher contingent on positive interim/final analysis results from its tafenoquine trial in severe babesiosis patients, with potential NDA submission targeted before Q1 2028. This represents a material regulatory development plan for a clinical-stage pharmaceutical company, but does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M&A, impairment, or other defined event types). The disclosure is material to investors assessing the company's development pipeline and regulatory strategy, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 5.03
Silo Pharma, Inc. implemented a 1-for-15 reverse stock split of its Common Stock, effective June 2, 2026, which proportionately reduced the Company's issued, outstanding, and authorized shares. This capital structure change affects share price, option and warrant exercise prices, and equity plan reserves, and may reflect efforts to address listing compliance requirements.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 8.01
TG Therapeutics disclosed positive Phase 1 clinical trial data for a subcutaneous formulation of ublituximab (BRIUMVI®) in relapsing multiple sclerosis. While clinical trial results can be material to investors assessing pipeline value and competitive positioning, this disclosure does not fit neatly into the more specific event categories (earnings_release, exec_departure, ma_activity, etc.). The positive PK/PD and safety data would reasonably affect an investor's assessment of the company's drug development prospects, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-03
The filing discloses entry into a material definitive agreement (Item 1.01) involving assignment of a debt instrument. While the transaction involves a related party and a previously impaired asset, it does not cleanly fit the standard taxonomy categories. The company assigned a $113,752 promissory note (original $100,000 principal plus $13,752 accrued interest) to SB Technology Holdings for $1,000 cash, reflecting the note's impaired status. This is material to investors as it involves a significant asset disposition and related-party transaction, but the event is best classified as "other_material" rather than forced into M&A or impairment categories, as it represents a debt assignment/disposition rather than a traditional acquisition or write-down disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 55%
filed 2026-06-03
Item 8.01
The Item 8.01 disclosure references multiple material transaction documents executed on May 31, 2026—including a Stock Purchase Agreement with Tacora Capital LP, a Loan Agreement with Cumberland Coal Corporation, a Subordination Agreement, and a Contingent Performance Note—but the actual substance of these transactions is not detailed in the 8-K text itself; it is incorporated by reference to the press release (Exhibit 99.1). Without access to the press release content, the precise nature of the transaction cannot be definitively classified. The structure suggests either a significant acquisition, financing arrangement, or restructuring involving Range Impact and Cumberland Coal entities, but the event type cannot be confidently assigned to ma_activity, dilutive_issuance, or covenant_breach without the exhibit details.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 7.01
FingerMotion disclosed a strategic initiative to develop modular AI-focused edge computing infrastructure, representing a material expansion of the company's business strategy and long-term roadmap. While the disclosure is furnished under Item 7.01 (Regulation FD) rather than a more specific Item, the announcement of a new infrastructure business line targeting the AI inference market—described by the CEO as "a natural extension of our technology platform and a potential driver of long-term shareholder value"—would affect a reasonable investor's assessment of the company's growth prospects and capital allocation strategy. This does not fit neatly into M&A activity, earnings release, or other narrower categories, making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
The Board approved a four-for-one stock split effected as a stock dividend, with specified record and payment dates, affecting share count and equity valuation metrics.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
OUTFRONT Media announced the pricing of $500 million in senior notes due 2034, a material debt issuance that affects the company's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 8.01
The Board amended the 2026 Repurchase Program effective June 3, 2026, to impose a 45% voting power ownership cap on any single shareholder, materially constraining the Company's ability to execute its previously authorized $1.25 billion repurchase program.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-03
Item 8.01
The filing discloses a quarterly cash dividend declaration of $0.0625 per share by the Board of Directors. While dividend declarations are routine corporate actions, this disclosure in an 8-K Item 8.01 suggests the company views it as material to investors. However, it does not fit cleanly into any of the more specific event categories (earnings, executive changes, M&A, impairments, etc.), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 7.01
The disclosure confirms full-year 2026 guidance and provides a Q2 update showing low-single-digit comparable store sales growth tracking, along with a repurchase program status update ($20M of $50M authorized repurchased). While guidance confirmation and operational updates are material to investors assessing company performance, this does not fit neatly into the specific event categories (not an earnings release, not a restatement, not an M&A event, etc.). The Item 7.01 Regulation FD Disclosure format and forward-looking nature of the guidance, combined with the operational update on e-commerce migration and comparable sales trends, warrant classification as a material event that does not fit the more specific taxonomy.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-03
Item 8.01
The filing discloses a dividend declaration of $9.96 per share, which is a material distribution to shareholders. While dividend declarations are routine for closed-end funds, this specific amount and the formal 8-K disclosure indicate materiality to investors. However, this does not fit cleanly into the standard taxonomy categories (it is not an earnings release, compensation arrangement, or other defined event type), warranting classification as "other_material."
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 7.01
The disclosure announces receipt of a $25–$30 million order from an existing customer, which is material in scale and would affect a reasonable investor's assessment of near-term revenue and business momentum. However, the filing does not fit neatly into the standard taxonomy (not an earnings release, M&A activity, or other defined event type), and the cautionary language about future deployment timing and market conditions introduces uncertainty about execution. This is best classified as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 8.01
OPAL Fuels announced commencement of construction on two RNG facilities (50/50 joint venture with GFL Environmental) expected to produce 15 million gasoline gallon equivalents annually. This represents material capital deployment and expansion of the Company's RNG production and distribution infrastructure, which is central to its business strategy. While not a classic M&A transaction, the joint venture facility development and associated production capacity are material to investors assessing the Company's growth trajectory and operational scale.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 3.03
Cardlytics effected a 1-for-10 reverse stock split and reduction in authorized shares, both approved by stockholders via Charter Amendment filed June 3, 2026. The reverse split is a material capital structure adjustment affecting share count and trading mechanics.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
KeyCorp is recasting segment financial information in its 2025 Form 10-K to reflect a change in segment reporting implemented in Q1 2026, specifically the reallocation of centrally managed interest rate risk from Consumer Bank and Commercial Bank segments to the Other segment. While the company explicitly states this is "not an amendment or restatement" and there is "no impact on the Company's consolidated financial statements," the recast affects how segment results are presented and disclosed, which is material to investors evaluating business unit performance. The filing is required under SEC rules when a registrant makes accounting changes and subsequently files new registration or proxy statements incorporating prior period financials.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-03
Item 8.01
RadNet disclosed a proposed amendment to its First Lien Credit Agreement to add an incremental term loan of $200 million. While this represents a material financing event that would affect investor assessment of the company's capital structure and liquidity, it does not fit cleanly into the more specific categories (ma_activity applies to acquisitions/dispositions, dilutive_issuance to equity sales, covenant_breach to defaults). The amendment itself is a debt restructuring or refinancing activity that is material but lacks a dedicated taxonomy category.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-03
Item 7.01
The filing discloses a corporate update on "NYSE compliance process and strategic transaction initiatives" via press release. While the Item 7.01 disclosure itself is vague, the reference to NYSE compliance suggests potential delisting risk or listing status concerns, and "strategic transaction initiatives" suggests possible M&A activity. Without access to the full press release (Exhibit 99.1), the most appropriate classification is other_material, as the disclosure touches on material matters (compliance and transactions) but the specific nature and materiality cannot be fully determined from the Item text alone.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-06-03
Item 8.01
Cabaletta Bio disclosed clinical trial data and development updates for rese-cel across its autoimmune portfolio, including encouraging early preconditioning-free lupus findings and anticipated regulatory milestones (SSc registrational program initiation in 4Q26, DM/ASyS topline data in mid-2027, BLA submission in 2H27). For a clinical-stage biotech company, positive clinical trial results and development progress are material to investor assessment of pipeline value and regulatory prospects.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-03
Item 8.01
FortuneX Acquisition Corp consummated its IPO on May 26, 2026, raising $75 million in gross proceeds from 7.5 million units at $10.00 per unit, with simultaneous sponsor purchases of $2.975 million in private placement units. While this is a significant capital-raising event material to investors, it does not fit neatly into the standard taxonomy categories (earnings_release, ma_activity, dilutive_issuance). The disclosure is primarily informational about the IPO closing and trust account establishment rather than a forward-looking material event like a going concern or covenant breach. This is classified as other_material because it represents a transformational liquidity event for a SPAC that would affect investor assessment, but lacks a dedicated taxonomy category.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-02
Item 8.01
JCP&L announced an extension of its debt exchange offer covering $1.35 billion in aggregate principal amount of senior notes (4.150% due 2029, 4.400% due 2031, and 5.150% due 2036), extending the expiration from June 1 to June 15, 2026. While this involves refinancing activity and debt management, it does not fit cleanly into the more specific event categories (not an M&A transaction, not a covenant breach, not a restatement or impairment). The extension of a material debt exchange offer is material to investors assessing the registrant's capital structure and liquidity management, warranting disclosure under Item 8.01.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-02
Item 8.01
The disclosure announces a two-for-one forward stock split effected through an amendment to the Certificate of Incorporation, with a record date of June 25, 2026 and distribution on June 30, 2026. While stock splits are material corporate actions affecting share structure and investor holdings, they do not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, impairment, or other defined event types). This is classified as other_material because it is a significant capital structure event that would affect a reasonable investor's assessment of share ownership and trading mechanics.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-02
Item 8.01
The Buckle announced a quarterly dividend of $0.35 per share, representing a material capital allocation decision affecting shareholder returns.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-02
Item 8.01
Arch Capital Group announced cash tender offers by its subsidiaries to repurchase up to $350 million in outstanding senior notes (5.144% notes due 2043 and 5.031% notes due 2046). While this is a material capital allocation and debt management activity that would affect investor assessment of the company's financial position and strategy, it does not fit cleanly into the more specific M&A or debt covenant categories—it is a voluntary debt repurchase program rather than a merger, acquisition, or covenant breach. This is best classified as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-06-02
Item 8.01
The filing discloses a press release dated June 2, 2026, under Item 8.01 (Other Events) but provides no substantive detail about the press release's content. Without access to Exhibit 99.1, the specific nature of the event cannot be determined. Given that Comcast is a major public company and the disclosure warrants an 8-K filing, the event is presumed material, but the event type cannot be reliably classified into a more specific category.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-02
Item 8.01
American Tower Corporation announced a partial redemption of €250 million of its €600 million outstanding 4.125% senior unsecured notes due 2027, with a redemption date of June 18, 2026. While this is a material debt management action affecting the company's capital structure and outstanding obligations, it does not fit neatly into the more specific event categories (covenant_breach, ma_activity, or material_impairment). The redemption is a routine debt reduction exercise executed within the contractual terms of the indenture, making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-02
Item 7.01
Rezolute issued a press release on June 2, 2026 announcing an interim update on its upLIFT study, a clinical trial. While the actual content of the update is not provided in this Item 7.01 disclosure (only boilerplate forward-looking statements and liability disclaimers are shown), interim clinical trial results can be material to investors assessing the company's pipeline and prospects. Without visibility into whether the update was positive, negative, or neutral, and lacking the substantive details, this is best classified as other_material rather than a more specific category.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-02
Item 7.01
The disclosure is a guidance update issued via press release on June 2, 2026, revising previously provided guidance from May 7, 2026 for Q2 and full-year fiscal 2026. While guidance updates can be material to investors, the filing does not disclose the specific nature, direction, or magnitude of the revision, making it difficult to classify as a standard earnings_release (which typically involves actual results) or fit cleanly into other defined categories. The materiality depends on the substance of the revision, which is not detailed in this Item 7.01 disclosure itself.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-02
Item 8.01
The disclosure reports receipt of approximately $28.7 million in warrant exercise proceeds in April-May 2026, increasing cash from $107.1 million to approximately $135.8 million, and notes 196.6 million shares outstanding as of June 2, 2026. While warrant exercises are a form of dilutive issuance, the filing emphasizes the cash proceeds and liquidity position rather than the equity issuance mechanics, and does not clearly indicate this was a private placement or PIPE transaction. The material cash infusion and updated share count are relevant to investor assessment, but the event does not fit cleanly into the dilutive_issuance category (which typically covers unregistered private placements) or any other specific taxonomy item.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-02
Item 8.01
The Board declared a cash distribution of $0.31 per share, which is a material capital allocation decision affecting shareholders. While routine dividend declarations are sometimes not considered material, the specific disclosure in an 8-K Item 8.01 and the per-share amount suggest this is a significant distribution event. However, this does not fit cleanly into the more specific event categories (it is not an earnings release, executive action, M&A, impairment, or other defined event type), so "other_material" is the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-02
Item 3.03
The Company designated 1,000,000 shares of Series C Convertible Preferred Stock via Articles Supplementary, materially modifying the capital structure and imposing distribution restrictions on junior and parity securities.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-02
Item 7.01
TXNM Energy's subsidiaries disclosed significant regulatory filings: TNMP's comprehensive settlement in a base rate review before the PUCT and PNM's application for approval of carbon-free generation resources. These regulatory matters are material to investors assessing the company's regulatory environment and future earnings.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-02
Item 1.01
The Company entered into a Third Amendment to its Shareholders Rights Agreement on June 2, 2026, eliminating the 'Acting in Concert' defined term while retaining other anti-takeover protections. This governance amendment affects shareholder assessment of takeover risk and Board authority.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-02
Item 8.01
The disclosure announces alignment with the FDA on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in IgA Nephropathy, with results expected in Q3 2026 and a planned supplemental BLA submission in Q4 2026. This represents a material regulatory milestone and timeline acceleration for a key clinical program, but does not fit neatly into the more specific event categories (it is neither a completed M&A transaction, a restatement, an executive change, nor a cybersecurity incident). The forward-looking nature and regulatory significance make it material to investors assessing the company's pipeline progress.
View raw filing on EDGAR →